Aurobindo Pharma, BSE Limited among top losers on Nifty Midcap 150
At 9:30 am on Tuesday, several stocks were facing downward pressure, with Aurobindo Pharma leading the declines on the Nifty Midcap 150. Aurobindo Pharm's stock was trading at Rs 1,154.00, a 2.62% decrease from its previous close. Other notable losers included BSE Limited, trading at Rs 2,583.90 with a fall of 1.98%, and Kalyan Jeweller, priced at Rs 572.80, down by 1.93%. Lupin and 360 ONE WAM also experienced declines, trading at Rs 1,948.70 (down 1.51%) and Rs 1,235.20 (down 1.42%) respectively.
Aurobindo Pharma Limited Financial Highlights:
Aurobindo Pharma Limited has demonstrated notable financial performance over the past few years. The company's consolidated revenue has steadily increased, reaching Rs 31,723.73 Crore for the year-ending March 2025, compared to Rs 29,001.87 Crore in the previous year. Net profit also saw a rise, with Rs 3,515.26 Crore reported for the year-ending March 2025, up from Rs 3,186.13 Crore in the previous fiscal year. The earnings per share (EPS) stood at Rs 59.81 for the year-ending March 2025, an increase from Rs 54.16 in the previous year. The company’s book value per share (BVPS) has also consistently grown, reaching Rs 562.21 in March 2025, compared to Rs 509.49 in the previous year.
Aurobindo Pharma Limited Key Financial Metrics:
HeadingMar 2021Mar 2022Mar 2023Mar 2024
Mar 2025Revenue (Rs Crore)24,774.6223,455.4924,855.3829,001.87
31,723.73Net Profit (Rs Crore)5,389.182,678.361,939.323,186.13
3,515.26EPS (Rs)91.0545.1932.9054.16
59.81BVPS (Rs)374.28419.42458.30509.49
562.21ROE (%)24.3210.777.1810.63
10.67Debt to Equity0.230.100.180.21
0.24
Aurobindo Pharma's quarterly financial performance shows a consistent revenue stream, with the quarter-ending March 2025 reporting Rs 8,382.12 Crore, compared to Rs 7,580.15 Crore in the same quarter the previous year. Net profit for the quarter-ending March 2025 was Rs 935.02 Crore, slightly higher than the Rs 920.01 Crore reported for the quarter-ending March 2024.
BSE Limited Financial Highlights:
BSE Limited has exhibited strong financial growth. The company's consolidated revenue has significantly increased, reaching Rs 3,212.04 Crore for the year-ending March 2025, compared to Rs 1,592.50 Crore in the previous year. Net profit also saw a substantial rise, with Rs 1,239.73 Crore reported for the year-ending March 2025, up from Rs 699.84 Crore in the previous fiscal year. The earnings per share (EPS) stood at Rs 96.55 for the year-ending March 2025, an increase from Rs 56.66 in the previous year. The company’s book value per share (BVPS) has also consistently grown, reaching Rs 326.84 in March 2025, compared to Rs 255.24 in the previous year.
BSE Limited Key Financial Metrics:
HeadingMar 2021Mar 2022Mar 2023Mar 2024
Mar 2025Revenue (Rs Crore)501.37743.15924.841,592.50
3,212.04Net Profit (Rs Crore)98.55180.75156.42699.84
1,239.73EPS (Rs)30.9418.5116.0656.66
96.55BVPS (Rs)559.09206.26208.86255.24
326.84ROE (%)5.819.588.1623.57
29.97Debt to Equity0.000.000.000.00
0.00
BSE Limited's quarterly financial performance shows a significant revenue stream, with the quarter-ending March 2025 reporting Rs 916.97 Crore, compared to Rs 544.77 Crore in the same quarter the previous year. Net profit for the quarter-ending March 2025 was Rs 478.04 Crore, substantially higher than the Rs 82.49 Crore reported for the quarter-ending March 2024.
Kalyan Jeweller Financial Highlights:
Kalyan Jeweller has demonstrated notable financial performance over the past few years. The company's standalone revenue has steadily increased, reaching Rs 22,707.90 Crore for the year-ending March 2025, compared to Rs 20,010.82 Crore in the previous year. Net profit also saw a rise, with Rs 3,306.26 Crore reported for the year-ending March 2025, up from Rs 1,935.57 Crore in the previous fiscal year. The earnings per share (EPS) stood at Rs 71.95 for the year-ending March 2025, an increase from Rs 42.05 in the previous year. The company’s book value per share (BVPS) has also consistently grown, reaching Rs 376.77 in March 2025, compared to Rs 315.41 in the previous year.
Kalyan Jeweller Key Financial Metrics:
HeadingMar 2021Mar 2022Mar 2023Mar 2024
Mar 2025Revenue (Rs Crore)15,162.9616,405.4816,641.6620,010.82
22,707.90Net Profit (Rs Crore)1,226.60-1,509.72447.691,935.57
3,306.26EPS (Rs)26.84-33.659.4642.05
71.95BVPS (Rs)305.45268.91275.67315.41
376.77ROE (%)8.81-12.573.4513.39
19.07Debt to Equity0.220.320.340.19
0.30
Kalyan Jeweller's quarterly financial performance shows a consistent revenue stream, with the quarter-ending March 2025 reporting Rs 4,485 Crore, compared to Rs 3,395 Crore in the same quarter the previous year. Net profit for the quarter-ending March 2025 was Rs 1,291 Crore, significantly higher than the Rs 384 Crore reported for the quarter-ending March 2024.
Lupin Financial Highlights:
Lupin has demonstrated notable financial performance over the past few years. The company's standalone revenue has steadily increased, reaching Rs 16,967 Crore for the year-ending March 2025, compared to Rs 14,666 Crore in the previous year. Net profit also saw a rise, with Rs 3,972 Crore reported for the year-ending March 2025.
Lupin Key Financial Metrics:
HeadingMar 2021Mar 2022Mar 2023Mar 2024
Mar 2025Revenue (Rs Crore)11,05511,77111,25814,666
16,967Net Profit (Rs Crore)1,258-1884252,326
3,972
360 ONE WAM Financial Highlights:
360 ONE WAM has demonstrated notable financial performance over the past few years. The company's consolidated revenue has steadily increased, reaching Rs 3,295.09 Crore for the year-ending March 2025. Net profit also saw a rise, with Rs 1,015.30 Crore reported for the year-ending March 2025.
360 ONE WAM Key Financial Metrics:
HeadingMar 2021Mar 2022Mar 2023Mar 2024
Mar 2025Revenue (Rs Crore)1,611.631,850.651,974.662,507.03
3,295.09Net Profit (Rs Crore)369.19577.74657.89804.21
1,015.30
Aurobindo Pharm's stock was trading at Rs 1,154.00, a 2.62% decrease from its previous close.